REG - Theracryf PLC - Master Service Agreement signed for Ox-1 programme

TheracryfAnnouncement

12/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250512:nRSL1607Ia&default-theme=true

RNS Number : 1607I  Theracryf PLC  12 May 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Master Service Agreement signed for Orexin-1 programme* development

 

Pharmaron appointed as contract research organisation

 

Alderley Park, UK - 12 May 2025: TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on neuropsychiatry and oncology, has signed
a Master Service Agreement ("MSA", or the "Agreement") with leading contract
research organisation ("CRO") Pharmaron UK Ltd ("Pharmaron") to progress
development of the Company's Orexin-1 ("Ox-1") addiction programme.

 

Under the Agreement, Pharmaron will provide services to enable completion of
the remaining preclinical data packages necessary to support an application
for clinical trial authorisation (IND/CTA). The activities will include
manufacturing scale up, formulation and clinical drug supply together with
regulatory-standard toxicology work - the last stages of preclinical drug
development before administration in humans.  As noted at the time of the
Company's recent fundraise, a substantial part of the proceeds will be
allocated to this new, key programme for the Company. Work under the MSA is
expected to commence imminently, further information on each work package will
be announced at initiation and completion, with full completion of all studies
necessary for IND/CTA application anticipated in H2 2026.

 

Dr Huw Jones, TheraCryf CEO said:

"Following our £4.25m gross fundraise in the first quarter of this year, we
are now moving at pace with our acquired and potentially most valuable
programme, Ox-1. Blocking the Ox-1 receptor has the potential to alleviate a
number of addictive and impulsive conditions. We look forward to proceeding
towards clinical trials in man as quickly and efficiently as possible with
Pharmaron as our development partner."

 

Dr Helen Kuhlman, TheraCryf CBO added:

"We evaluated a number of proposals from potential providers and throughout
this rigorous process were impressed by the knowledge and expertise shown by
the Pharmaron team. The positive external references we received regarding the
quality and delivery of their work added to our confidence in selecting them
as our provider to take the Orexin programme forward."

 

Dr Filipa Antunes, Pharmaron Business Executive Director, commented:

"We are honoured to have been selected as TheraCryf's partner to advance this
exciting and important programme. Our integrated capabilities in preclinical
development and manufacturing are well positioned to help ensure a smooth and
efficient transition to first-in-human studies. We are truly delighted to
collaborate with the TheraCryf team and look forward to supporting them in
bringing new hope to patients affected by addiction and related disorders"

*Competitive antagonist of the orexin-1 receptor

 

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

 Dr Huw Jones, CEO                                           enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Turner Pope Investments (Joint Broker)                      +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Cavendish Capital Markets (NOMAD & Joint Broker)            +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

 Vigo Consulting                                             +44 (0)20 7390 0231

 Rozi Morris                                                 theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma**
and neurodevelopmental disorders [**orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C%3A/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
.

About Pharmaron

 

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier service provider for
the life sciences industry. Founded in 2004, Pharmaron has invested in its
people and facilities and established a broad spectrum of research,
development, and manufacturing service capabilities throughout the entire drug
discovery, preclinical, and clinical development process across multiple
therapeutic modalities, including small molecules
(https://www.pharmaron.com/modalities/small-molecule-services/) , biologics,
(https://www.pharmaron.com/modalities/biologics-services/)  and CGT products
(https://www.pharmaron.com/modalities/cell-and-gene-therapy-services/) .

With over 21,000 employees and operations in China, the U.S., and the U.K.,
Pharmaron has an excellent track record in delivering R&D solutions to its
partners in North America, Europe, Japan, and China.

For further information, please visit www.pharmaron.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSEESUEISEFI